What the business is, and whether it's a good one at a fair price.
Operates as an R&D-driven pharmaceutical platform with two principal divisions. The CDMO (Contract Development and Manufacturing Organization) division supplies small-molecule active ingredients and finished dosage forms to global innovator customers from late-stage clinical through commercial supply, and earned ₹835 crores in Q1 FY27 (+69% YoY) with 55% of the mix from commercial supplies. The division is also investing in newer modalities — peptides, antibody-drug conjugates (ADCs), gene therapy and precision fermentation — with a 400+ KL fermentation Phase-1 capacity targeted to be live by end-CY2026. The Affordable Medicines division makes generic APIs and formulations for HIV (antiretrovirals, or ARVs), oncology and other therapeutic categories, recording ₹1,156 crores in Q1 FY27 (+10% YoY), with ARVs at roughly one-third of division revenue and a cumulative filing base of 92 Drug Master Files and 96 formulation dossiers. R&D spending ran at 5.8% of revenue in Q1 FY27 and the company held 24 quality audits in the quarter with no critical findings. Direct export intensity is stated at 55–60%, and FY27 capex guidance was raised to ₹2,000 crores (from ₹1,500 crores) to fund customer-led capacity, with cumulative FY22-27 capex exceeding ₹4,700 crores. Costs are dominated by materials (41% of FY26 revenue), with employee cost at 13.1% and depreciation at 7.0%; capital expenditure itself is reported at 15.7% of FY26 revenue.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from LAURUS LABS LIMITED's filed financials and exchange disclosures
LAURUS LABS LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol LAURUSLABS.
Yes. Over the trailing twelve months LAURUS LABS LIMITED reported a net profit of ₹1,091 Cr on revenue of ₹7,270 Cr.
Yes. The dividend yield is 0.08% at the current price. It paid out 10% of its profit as dividend in FY26.
No. Debt stands at 0.44× equity, and it carries net debt of ₹2,285 Cr. That is lower than 21% of its 171 Pharmaceuticals peers.
On trailing P/E, LAURUS LABS LIMITED ranks 154 of 169 in Pharmaceuticals — cheaper than 9% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session LAURUS LABS LIMITED moves 1.13% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by LAURUS LABS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
